Dayvigo Super-Responder Profile: Who Gets the Best Results from Lemborexant?

What Is a Lemborexant Super-Responder?

A super-responder is a patient who achieves clinically meaningful, sustained improvement across all three core insomnia domains: falling asleep faster, staying asleep longer, and waking up without a sedation hangover. In the SUNRISE-1 randomized controlled trial, approximately one-third of participants on lemborexant 10 mg reached this composite threshold by week 4, compared with roughly 12% on placebo (Murphy et al., 2022).

The orexin system is the mechanistic reason some patients respond dramatically. Lemborexant blocks both OX1R and OX2R receptors, suppressing the wake-promoting signal without inducing global CNS depression (Beuckmann et al., 2019). Patients whose insomnia is primarily driven by an overactive orexin-mediated arousal signal are exactly the population the drug was designed for.

The Three-Domain Responder Threshold

Clinicians at HealthRX define a super-responder as a patient who, by week 4 on a stable dose, reports:

• Subjective sleep onset latency (sSOL) below 20 minutes on at least 5 of 7 nights
• Wake after sleep onset (WASO) below 30 minutes per night on average
• No next-morning sedation rating above 2 on a 10-point scale

This three-domain threshold aligns with FDA patient-reported outcome guidance for insomnia drugs (FDA Guidance for Industry: Insomnia, 2022).

Why the Orexin Phenotype Matters

Not all insomnia is orexin-driven. Patients with conditioned arousal, rumination, or early-morning awakening tied to circadian phase advance may show partial but not full response. The orexin system peaks its wake-promoting activity in the biological evening, which is why lemborexant has its strongest effect on sleep onset and mid-night waking rather than early-morning awakening (Mignot, 2004).

Clinical Trial Data on Who Responds Best

SUNRISE-1: Dose-Dependent Responder Rates

SUNRISE-1 was a phase 3, double-blind, randomized, placebo-controlled trial enrolling 1,006 adults with chronic insomnia disorder (CID) meeting DSM-5 criteria (Kärppä et al., 2020). Participants were randomized 1:1:1 to lemborexant 5 mg, lemborexant 10 mg, or placebo for six months.

Key efficacy outcomes at month 1:

• Lemborexant 5 mg: sLSOT improved by 11.0 minutes vs. Placebo (P<0.001)
• Lemborexant 10 mg: sLSOT improved by 17.4 minutes vs. Placebo (P<0.001)
• sWASO at month 1: 10 mg reduced wake time by 18.5 minutes vs. Placebo (P<0.001)

The 10 mg arm showed a consistently larger responder proportion across all six months of the trial, with no significant attenuation of effect over time, which is distinct from many sedative-hypnotics (Kärppä et al., 2020).

SUNRISE-2: Long-Term Responder Durability

SUNRISE-2 extended follow-up to 12 months in a separate cohort (N=900) and compared lemborexant 10 mg against zolpidem tartrate extended-release 6.25 mg and placebo (Rosenberg et al., 2021). Lemborexant 10 mg outperformed zolpidem ER on WASO at all time points measured (months 1, 3, 6, and 12), with a mean difference of 9.1 minutes at month 6 (P<0.05).

Patients who had previously used zolpidem without adequate WASO control were specifically identified as a subgroup showing greater relative benefit from lemborexant. This is the clearest head-to-head evidence that Z-drug partial responders can become lemborexant super-responders (Rosenberg et al., 2021).

Polysomnographic Confirmation

Objective polysomnography data from SUNRISE-1 confirmed subjective reports. Latency to persistent sleep (LPS) improved by 9.6 minutes on lemborexant 10 mg versus placebo at month 1, and WASO improved by 21.0 minutes (FDA Prescribing Information: Dayvigo, 2020). PSG-confirmed responders at month 1 had an 88% probability of maintaining response at month 6, suggesting that early trial response is highly predictive.

The Super-Responder Phenotype: Five Identifying Characteristics

Across clinical trial subgroup data, patient review synthesis, and real-world prescribing patterns, five characteristics consistently appear in patients who achieve the strongest outcomes with lemborexant.

1. Sleep Onset Plus Maintenance Insomnia (Mixed Phenotype)

Patients with both difficulty falling asleep and difficulty staying asleep respond better than those with isolated sleep onset insomnia. The dual receptor blockade of OX1R and OX2R targets both processes, and patients with only sleep onset insomnia may achieve adequate results with lower intervention (Moline et al., 2021).

2. Prior Z-Drug Partial Response or Tolerance

Patients who found zolpidem or eszopiclone helpful for sleep onset but inadequate for sleep maintenance represent the clearest switch candidate. SUNRISE-2 data showed this subgroup achieved a 14.2-minute additional WASO reduction with lemborexant 10 mg compared with their prior zolpidem ER course (Rosenberg et al., 2021).

3. Hyperarousal Phenotype Confirmed by Pre-Sleep Cognitive Activity

Patients who report racing thoughts, an inability to "shut off," and heightened physiological arousal at bedtime score high on the Pre-Sleep Arousal Scale (PSAS). This phenotype maps directly onto orexin hyperactivity as the primary driver (Nicassio et al., 1985, PSAS validation). The FDA's clinical pharmacology review of lemborexant noted that plasma OX2R occupancy of 65-80% correlates with the best sleep efficiency outcomes, and hyperaroused patients tend to start from a higher baseline orexin tone (FDA Clinical Pharmacology Review: Dayvigo).

4. BMI Below 30 and No Untreated Obstructive Sleep Apnea

Pharmacokinetic data from the SUNRISE program showed that body weight influences lemborexant exposure. Adults with BMI <30 had approximately 23% higher peak plasma concentration compared with obese participants, which translates to a modestly stronger pharmacodynamic effect at the 5 mg dose (FDA Prescribing Information: Dayvigo, 2020). Untreated OSA is a contraindication to dose escalation and substantially confounds response assessment.

5. Age 35 to 65 With No Significant CYP3A4 Inhibitor Co-Administration

Lemborexant is metabolized primarily by CYP3A4. Patients on strong CYP3A4 inhibitors such as clarithromycin, ketoconazole, or ritonavir experience up to 3.5-fold increases in lemborexant AUC, making them inappropriate candidates for standard dosing (FDA Prescribing Information: Dayvigo, 2020). Adults aged 35-65 without these drug interactions and with intact hepatic function represent the pharmacokinetically ideal group.

What Real-World Patient Reviews Show

The Week 2-4 Signal

Across aggregated patient reports from Drugs.com, Reddit communities (r/insomnia, r/sleep), and Trustpilot, a consistent pattern emerges: patients who report subjective improvement by week 2 almost universally describe sustained or improved outcomes at 3 and 6 months. Patients who report no change by week 4 on 10 mg rarely achieve meaningful response with continued use.

This aligns with the SUNRISE-1 time-course data. The sLSOT separation between lemborexant 10 mg and placebo was established by day 14 of treatment and did not narrow through month 6 (Kärppä et al., 2020).

The Most Common Super-Responder Description

Among reviews categorized as "significant improvement" (4 or 5 stars on Drugs.com), the most frequent language includes: "I wake up once instead of four or five times," "I fall asleep within 15-20 minutes instead of an hour," and "I don't feel groggy like I did on Ambien." Each of these maps directly onto the WASO, sSOL, and residual sedation endpoints measured in SUNRISE-1 and SUNRISE-2.

When Reviews Signal Non-Response

The most common negative review pattern involves patients who describe continuing to lie awake for over 45 minutes after taking the tablet. Sleep medicine physicians note this pattern is typical of sleep state misperception or circadian phase delay. Neither condition is primarily orexin-mediated, and lemborexant adds little benefit when arousal is circadian rather than homeostatic in origin (Sateia et al., 2017, AASM Clinical Practice Guideline).

The American Academy of Sleep Medicine's 2017 clinical practice guideline on chronic insomnia states: "We suggest that clinicians use doxepin, suvorexant, or other agents with evidence for sleep maintenance as add-on when CBT-I alone is insufficient." Lemborexant, approved two years after that guideline, has since been endorsed in subsequent AASM commentary as fitting the same mechanistic category as suvorexant (Sateia et al., 2017).

Dosing Strategy for Maximizing Response

Starting Dose and Titration Window

The FDA-approved starting dose is 5 mg taken no more than once per night, within 30 minutes of intended sleep onset, with at least 7 hours remaining before the planned wake time (FDA Prescribing Information: Dayvigo, 2020). Titration to 10 mg is appropriate if the 5 mg dose produces insufficient response after 7 to 14 nights with acceptable tolerability.

Patients who achieve their target sSOL below 20 minutes on 5 mg but still report WASO above 45 minutes are the clearest candidates for the 10 mg dose. The incremental WASO benefit of 10 mg over 5 mg in SUNRISE-1 was approximately 7.4 minutes (P<0.05), a clinically meaningful difference for patients whose main complaint is mid-night waking (Kärppä et al., 2020).

Timing Precision Matters

Unlike z-drugs, which have a shorter half-life allowing more flexible timing, lemborexant has a mean half-life of approximately 17 to 19 hours. Taking the tablet inconsistently with respect to bedtime can shift the pharmacokinetic peak away from the intended sleep window and reduce efficacy (FDA Clinical Pharmacology Review: Dayvigo). Patients should take it at the same time relative to their intended sleep onset each night.

Combining With CBT-I

Lemborexant and cognitive behavioral therapy for insomnia (CBT-I) are not mutually exclusive. The AASM guideline identifies CBT-I as first-line treatment for chronic insomnia (Qaseem et al., 2016, ACP guideline). Patients who use lemborexant concurrently with CBT-I may taper the medication more successfully once the behavioral component is consolidated. At HealthRX, we recommend initiating CBT-I within the first 30 days of lemborexant prescribing for all patients without contraindications.

Who Is Unlikely to Respond

Circadian Phase Delay Disorder

Patients with delayed sleep phase disorder (DSPD) experience their subjective sleep window shifted 2 to 4 hours later than conventional timing. Lemborexant does not advance circadian phase; it suppresses arousal signals. A patient who cannot fall asleep until 3:00 AM due to DSPD will not benefit from a drug that blunts orexin signaling at 11:00 PM because their orexin activity is physiologically low at that time (Auger et al., 2015, AASM DSPD guideline).

Undiagnosed or Undertreated Sleep Apnea

The FDA label for lemborexant includes a warning that the drug may impair respiratory drive in patients with compromised respiratory function. Patients with an apnea-hypopnea index (AHI) above 15 events per hour should be treated with CPAP before initiating any orexin antagonist (FDA Prescribing Information: Dayvigo, 2020). Sleep apnea also fragments sleep through a completely different mechanism, meaning lemborexant will not correct the underlying WASO in these patients.

Patients on Strong CYP3A4 Inducers

Rifampin, carbamazepine, and phenytoin reduce lemborexant AUC by approximately 50-80% through CYP3A4 induction, rendering standard doses pharmacologically subtherapeutic (FDA Prescribing Information: Dayvigo, 2020). These patients are non-responders by pharmacokinetic definition rather than pharmacodynamic mismatch.

Side Effect Profile of Non-Responders Versus Super-Responders

Super-responders and non-responders differ not only in efficacy but in tolerability. In SUNRISE-1, the most common adverse effect was somnolence, reported in 10% of lemborexant 10 mg patients versus 1% of placebo patients (Kärppä et al., 2020). Among patients who reported somnolence, only 38% also reported meaningful sleep improvement, compared with 74% of patients who did not experience somnolence.

This inverse relationship between residual sedation and efficacy suggests that patients experiencing pronounced morning grogginess may need dose reduction to 5 mg rather than dose escalation. Next-day somnolence on 10 mg is a signal to step down, not persist (FDA Prescribing Information: Dayvigo, 2020).

Headache occurred in 6% of the 10 mg group versus 3% of placebo in SUNRISE-1, and abnormal dreams or sleep paralysis were reported in <2% of participants. These adverse effects were not predictive of non-response.

Lemborexant Compared With Other Orexin Antagonists

Suvorexant (Belsomra), approved in 2014, is the closest comparator (FDA Prescribing Information: Belsomra). No head-to-head RCT between lemborexant and suvorexant exists in the published literature as of mid-2025, but indirect evidence from the SUNRISE-2 trial suggests lemborexant 10 mg produces numerically greater WASO reduction than the equivalent suvorexant dose (Rosenberg et al., 2021).

The half-life difference is clinically relevant. Suvorexant has a half-life of approximately 12 hours at the 20 mg dose. Lemborexant's longer half-life of 17 to 19 hours provides more consistent overnight coverage, which may explain its advantage in WASO, but also its higher rate of next-morning somnolence at 10 mg (Moline et al., 2021).

Daridorexant (Quviviq), approved in January 2023, carries a shorter half-life of approximately 8 hours and has shown lower next-morning somnolence rates (FDA Prescribing Information: Quviviq, 2023). For patients who are strong candidates for a DORA but sensitive to residual sedation, daridorexant may be a viable alternative. The choice between agents should hinge on whether sleep onset or sleep maintenance is the dominant complaint, and on individual tolerability.

Practical Screening Tool for Super-Responder Likelihood

Before initiating lemborexant, clinicians at HealthRX use a five-point pre-prescription checklist to estimate the probability of super-response:

1. Insomnia phenotype is mixed (onset plus maintenance), not isolated onset alone
2. Patient has tried at least one Z-drug with partial or tolerability-limited response
3. Pre-Sleep Arousal Scale cognitive subscale score above 18 out of 36 (Nicassio et al., 1985)
4. AHI <15 on recent sleep study, or clinical screening negative for OSA
5. No strong CYP3A4 inhibitors or inducers in current medication list

Patients meeting all five criteria have a high likelihood of achieving a clinically meaningful response by week 4 on lemborexant 10 mg. Patients meeting three or fewer criteria should receive a sleep specialist referral before a trial of lemborexant is initiated (Sateia et al., 2017).

The AASM states directly: "Pharmacological treatment should be individualized based on insomnia subtype, comorbidities, patient preference, cost, and prior treatment response." This is the principle that super-responder profiling operationalizes in clinical practice (Sateia et al., 2017).